for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Compugen Ltd. (USA)

CGEN.OQ

Latest Trade

18.86USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

3.83

 - 

19.89

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Compugen Reports Q2 Loss Per Share $0.08

July 30 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN REPORTS SECOND QUARTER 2020 RESULTS.Q2 LOSS PER SHARE $0.08.ENROLLMENT IN COM701 PHASE 1 MONOTHERAPY BIOMARKER-DRIVEN EXPANSION COHORT ON-TRACK.INITIATION OF TRIPLE COMBINATION STUDY ACCELERATING EVALUATION OF DNAM AXIS HYPOTHESIS ON-TRACK FOR 2H 2020.

Compugen Reports FDA Clearance Of IND Application For Phase 1/2 Triple Combination Study Of COM701

June 1 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1/2 TRIPLE COMBINATION STUDY OF COM701 WITH BRISTOL MYERS SQUIBB'S OPDIVO® (NIVOLUMAB) AND TIGIT INHIBITOR.COMPUGEN - ON-TRACK TO BEGIN TRIPLE COMBINATION STUDY DURING SECOND HALF OF 2020.COMPUGEN - COM701 TRIPLE COMBINATION STUDY TO EVALUATE SIMULTANEOUS BLOCKADE OF PVRIG, TIGIT & PD-1 IMMUNE CHECKPOINTS.

Compugen Reports Q1 Loss Per Share $0.10

May 6 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN REPORTS FIRST QUARTER 2020 RESULTS.Q1 LOSS PER SHARE $0.10.FOR NOW, WE ARE NOT CHANGING ANTICIPATED DATA READOUTS AND MILESTONES TIMELINES WE PREVIOUSLY PROVIDED.

Compugen Expands Intellectual Property Portfolio For Com701 With New European Composition Of Matter Patent

April 22 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN EXPANDS INTELLECTUAL PROPERTY PORTFOLIO FOR COM701 WITH NEW EUROPEAN COMPOSITION OF MATTER PATENT.COMPUGEN LTD - PATENT IS EXPECTED TO EXPIRE IN EUROPE NO EARLIER THAN FEBRUARY 2036.

Compugen Reports Q4 Loss Per Share $0.10

Feb 20 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS.Q4 LOSS PER SHARE $0.10.

Compugen Further Expands Intellectual Property Portfolio With New European Patent For Anti-Pvrig Antibodies

Compugen Ltd <CGEN.TA>::COMPUGEN FURTHER EXPANDS INTELLECTUAL PROPERTY PORTFOLIO WITH NEW EUROPEAN PATENT FOR ANTI-PVRIG ANTIBODIES.COMPUGEN LTD - PATENT IS EXPECTED TO EXPIRE IN EUROPE NO EARLIER THAN FEBRUARY 2036.

Compugen Reports Q3 Loss Per Share Of $0.10

Nov 11 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN REPORTS THIRD QUARTER 2019 RESULTS.Q3 LOSS PER SHARE $0.10.AS OF SEPTEMBER 30, 2019, CASH, CASH EQUIVALENTS, SHORT-TERM BANK DEPOSITS AND RESTRICTED CASH TOTALED $47.6 MILLION.

Compugen Presents Initial Clinical Data From Ongoing Phase 1 Trial Of Com701 In Patients With Advanced Solid Tumors At Sitc 2019

Nov 5 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN PRESENTS INITIAL CLINICAL DATA FROM ONGOING PHASE 1 TRIAL OF COM701 IN PATIENTS WITH ADVANCED SOLID TUMORS AT SITC 2019.COMPUGEN LTD - COM701 WAS WELL-TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED.COMPUGEN LTD - INITIAL SIGNALS OF ANTI-TUMOR ACTIVITY OBSERVED IN HEAVILY PRETREATED PATIENT POPULATION IN DOSE ESCALATION ARM OF STUDY.

Compugen Announces FDA Clearance Of Ind Application For Com902

Nov 4 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR COM902.COMPUGEN- UNDER IND, INTENDS TO INITIATE A PHASE 1 CLINICAL TRIAL IN PATIENTS WITH ADVANCED MALIGNANCIES.COMPUGEN LTD - PHASE 1 CLINICAL STUDY IN PATIENTS WITH ADVANCED MALIGNANCIES EXPECTED TO BEGIN IN EARLY 2020.

Compugen Ltd Files For Mixed Shelf Of Upto $200 Million

Aug 5 (Reuters) - Compugen Ltd <CGEN.TA>::COMPUGEN LTD FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up